Welcome to your Daily Dose of Health Tech Innovation!
Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.
We bring you expert-curated insights, emerging trends, and must-know updates from the digital health frontier.
Whether you’re a clinician, innovator, or health tech enthusiast, this roundup delivers what matters most.
Let’s dive into the future of health, one innovation at a time.
Paradigm Health Secures $78Million Series B to Expand Clinical Trials
Paradigm Health, the technology company rebuilding the clinical research ecosystem, announced an oversubscribed $78 million Series B financing. The round was led by ARCH Venture Partners, with participation from new investor DFJ Growth and existing investors F-Prime, General Catalyst, GV, Lux Capital, Mubadala Capital, the American Cancer Society’s BrightEdge Fund, and others, several of whom took super pro-rata positions.
Dario Digital Platform Shows Strong, Lasting BP Improvements
DarioHealth Corp., a global digital health company, announced the publication of new research in JMIR Cardio showing that personalized nudges delivered through its digital platform can lead to meaningful and lasting improvements in blood pressure. The study, titled The Impact of Digital Intervention Messages Targeting Users With High Blood Pressure Events: Retrospective Real-World Study, used real-world data from individuals using Dario’s platform and compared outcomes for people who received targeted messages with a similar group that did not receive them.
AstraZeneca Expands Hematology Presence at ASH 2025
AstraZeneca is showcasing significant progress in hematology at the 67th American Society of Hematology Annual Meeting and Exposition from December 6 to 9, 2025, presenting the largest presence the company has ever had at ASH. The company will feature 65 abstracts covering eight approved and investigational medicines, including 15 oral presentations, reflecting the breadth and depth of its hematology portfolio and pipeline. Key presentations include updated three-year follow-up data from the Phase I first-in-human trial of surovatamig, a CD19xCD3 T-cell engager, in patients with relapsed or refractory follicular lymphoma; early Phase Ib/II results for AZD0120, an investigational BCMAxCD19 CAR T-cell therapy, in relapsed or refractory multiple myeloma; long-term Phase III ECHO trial results for CALQUENCE in combination with bendamustine and rituximab for first-line mantle cell lymphoma; and additional data from the ALXN1210-TMA-314 Phase III trial evaluating ULTOMIRIS in pediatric patients with HSCT-associated thrombotic microangiopathy.
Ashish Varshneya Joins Evercore Healthcare Investment Banking
Evercore has announced that Ashish Varshneya has joined the firm as a senior managing director in its healthcare investment banking group, where he will focus on healthcare technology. He will be based in New York.
Dexcom Launches Dexcom Academy for Healthcare Education
Dexcom, Inc., a global leader in continuous glucose monitoring, has launched Dexcom Academy, a personalized learning platform designed by and for healthcare professionals. The platform is currently available in Belgium, Germany, Saudi Arabia, the Netherlands, and Spain, with additional launches planned across EMEA in 2026.
To share your insights, please write to us at sudipto@intentamplify.com
